Last reviewed · How we verify
NCT03534778
Prognostic Significance of Lymph Node Yield and Lymph Node Ratio Prospective Observational Study
trial testing Lymph Node Yield (LNY) and Lymph Node Ratio (LNR) in Head and Neck Cancer in 350 participants. Status unknown.
1 January 2022
Quick facts
| Lead sponsor | University of Roma La Sapienza |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 350 |
| Start date | 1 January 2019 |
| Primary completion | 1 January 2022 |
| Estimated completion | 1 January 2024 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Lymph Node Yield (LNY) and Lymph Node Ratio (LNR)
Conditions studied
- Head and Neck Cancer — all drugs for Head and Neck Cancer →
Sponsor
University of Roma La Sapienza
Who can join
18 and older, any sex, with Head and Neck Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
It is still unclear if Lymph Node Yield (LNY) and Lymph Node Ratio (LNR) may have a prognostic role in patients affected by carcinoma of the oral cavity and the oropharynx. Only retrospective studies are available. For this reason, this prospective, multi center, observational study should provide indications in this regard. Proper stratification by patients characteristics will allow to understand if LNY and LNR may enter in the future TNM staging system
Publications & conference data
2 peer-reviewed publications reference this trial (live from Europe PMC):
-
Lymph node yield and lymph node ratio in oral cavity and oropharyngeal carcinoma: Preliminary results from a prospective, multicenter, international cohort.
Iocca O, Di Maio P, De Virgilio A, Pellini R, et al · · 2020 · cited 28× · PMID 32380357 · DOI 10.1016/j.oraloncology.2020.104740 -
Prognostic significance of lymph node yield and lymph node ratio in patients affected by squamous cell carcinoma of the oral cavity and oropharynx: Study protocol for a prospective, multicenter, observational study.
Iocca O, Farcomeni A, De Virgilio A, Di Maio P, et al · · 2019 · cited 21× · PMID 30723839 · DOI 10.1016/j.conctc.2019.100324
Verify or expand the search:
- PubMed search for NCT03534778
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Head and Neck Cancer
Currently open trials in the same condition.
- NCT07318220 — Prehabilitation Protocol for Head and Neck Cancer Patients · NA · recruiting
- NCT07524114 — Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception · recruiting
- NCT07467083 — Development and Application of a Nurse-Led Preemptive Symptom Management Protocol for Head and Neck Cancer Patients Unde · Phase 3 · recruiting
- NCT07209189 — Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-esca · Phase 2 · recruiting
- NCT06837480 — Photobiomodulation in Head and Neck Cancer-Related Chronic Lymphedema · NA · recruiting
Other University of Roma La Sapienza trials
Trials by the same sponsor.
- NCT07485023 — Oral Versus Intravenous Iron for Anemia Diagnosed After 34 Weeks of Gestation · NA · not yet recruiting
- NCT07305519 — The Combined Effect of Magnesium, Palmitoylethanolamide, High-Molecular-weight Hyaluronic Acid, Vitamin B6, and Vitamin · NA · not yet recruiting
- NCT07520968 — ABX Versus CHX in NSPT: a RCT · NA · active not recruiting
- NCT07109596 — Integration of Clinical, Biological and Psycho-social Variables for a Gender-sensitive Frailty Prediction · recruiting
- NCT07490574 — Trial of Underwater Versus Gas-Insufflation Colorectal Endoscopic Submucosal DisseEtion · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03534778 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Roma La Sapienza
- Last refreshed: 19 April 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03534778.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing